<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02736799</url>
  </required_header>
  <id_info>
    <org_study_id>215CLD</org_study_id>
    <nct_id>NCT02736799</nct_id>
  </id_info>
  <brief_title>Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers</brief_title>
  <official_title>Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers: A Sham Device Controlled, Single Center Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vibrant Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vibrant Ltd.</source>
  <brief_summary>
    <textblock>
      The Vibrant capsule is a novel vibrating device for the treatment of gastrointestinal&#xD;
      disorders. The effect of different vibrations on the motor functions of the gastrointestinal&#xD;
      tract are unclear. The study will focus on the stomach in healthy volunteers.&#xD;
&#xD;
      The study will compare the effects of Vibrant capsule treatment and Sham capsule treatment on&#xD;
      gastric emptying and gastric motility in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastroduodenal manometry measurement of first hour postprandial distal antral motility index.</measure>
    <time_frame>5 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying of solids:T1/2 in minutes (scintigraphy)</measure>
    <time_frame>5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying of solids: lag time in minutes (scintigraphy)</measure>
    <time_frame>5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying at 1h (scintigraphy)</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying at 2h (scintigraphy)</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First 0.5h postprandial distal antral motility index (Gastroduodenal manometry)</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal Symptom assessments - VAS</measure>
    <time_frame>5 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Sham vibrating capsule</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham vibrating capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vibrant Capsule (1 vibration)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 vibration/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vibrant Capsule (3 vibration)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 vibrations/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vibrant Capsule (5 vibration)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 vibrations/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham vibrating capsule</intervention_name>
    <description>Sham device without vibration</description>
    <arm_group_label>Sham vibrating capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vibrant Capsule (1 vibration)</intervention_name>
    <description>1 vibration/min</description>
    <arm_group_label>Vibrant Capsule (1 vibration)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vibrant Capsule (3 vibration)</intervention_name>
    <description>3 vibration/min</description>
    <arm_group_label>Vibrant Capsule (3 vibration)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vibrant Capsule (5 vibration)</intervention_name>
    <description>5 vibration/min</description>
    <arm_group_label>Vibrant Capsule (5 vibration)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide written informed consent prior to any study procedures, and be willing&#xD;
             and able to comply with study procedures&#xD;
&#xD;
          2. No medical problems or chronic diseases, specifically, no type 2 diabetes mellitus&#xD;
&#xD;
          3. Body mass index of 18-35 kg/m2&#xD;
&#xD;
          4. Female subjects must have negative urine pregnancy tests and must not be lactating&#xD;
             prior to receiving study medication and radiation exposure. For females able to bear&#xD;
             children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier&#xD;
             method, or a double-barrier method of birth control must be used throughout the study.&#xD;
             Female subjects unable to bear children must have this documented in the medical&#xD;
             record [i.e., tubal ligation, hysterectomy, or post-menopausal (defined as a minimum&#xD;
             of one year since the last menstrual period)].&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable or unwilling to provide informed consent or to comply with study procedures&#xD;
&#xD;
          2. Diagnosis of gastrointestinal diseases&#xD;
&#xD;
          3. Structural or metabolic diseases that affect the gastrointestinal system&#xD;
&#xD;
          4. Unable to avoid the following over-the-counter medications 48 hours prior to the&#xD;
             baseline period and throughout the study:&#xD;
&#xD;
               1. Medications that alter gastrointestinal transit including laxatives, magnesium&#xD;
                  and aluminum containing antacids, prokinetics, erythromycin&#xD;
&#xD;
               2. Analgesic drugs including Nonsteroidal Anti-Inflammatory Drugs and COX-2&#xD;
                  inhibitors NOTE: stable doses of thyroid replacement, estrogen replacement,&#xD;
                  low-dose aspirin for cardioprotection, and birth control (but with adequate&#xD;
                  backup contraception as drug-interactions with birth control have not been&#xD;
                  conducted) are permissible.&#xD;
&#xD;
          5. History of recent surgery (within 60 days of screening)&#xD;
&#xD;
          6. Acute or chronic illness or history of illness which, in the opinion of the&#xD;
             investigator, could pose a threat or harm to the subject or obscure interpretation of&#xD;
             laboratory test results or interpretation of study data, such as frequent angina,&#xD;
             Class III or IV congestive heart failure, moderate impairment of renal or hepatic&#xD;
             function, poorly controlled diabetes, etc.&#xD;
&#xD;
          7. Any clinically significant abnormalities on physical examination or laboratory&#xD;
             abnormalities identified in the medical record, as determined by the investigator&#xD;
&#xD;
          8. Acute gastrointestinal illness within 48 hours of initiation of the baseline period&#xD;
&#xD;
          9. Females who are pregnant or breastfeeding&#xD;
&#xD;
         10. History of excessive alcohol use or substance abuse&#xD;
&#xD;
         11. Participation in an investigational study within the 30 days prior to dosing in the&#xD;
             present study&#xD;
&#xD;
         12. Any other reason, which in the opinion of the investigator, would confound proper&#xD;
             interpretation of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

